JP2021531005A5 - - Google Patents
Info
- Publication number
- JP2021531005A5 JP2021531005A5 JP2021502831A JP2021502831A JP2021531005A5 JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5 JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021502831 A JP2021502831 A JP 2021502831A JP 2021531005 A5 JP2021531005 A5 JP 2021531005A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- binding molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117208A JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700596P | 2018-07-19 | 2018-07-19 | |
| US62/700,596 | 2018-07-19 | ||
| US201862750968P | 2018-10-26 | 2018-10-26 | |
| US62/750,968 | 2018-10-26 | ||
| US201962793645P | 2019-01-17 | 2019-01-17 | |
| US62/793,645 | 2019-01-17 | ||
| PCT/US2019/042447 WO2020018820A1 (en) | 2018-07-19 | 2019-07-18 | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Division JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531005A JP2021531005A (ja) | 2021-11-18 |
| JP2021531005A5 true JP2021531005A5 (https=) | 2022-07-25 |
| JP7319348B2 JP7319348B2 (ja) | 2023-08-01 |
Family
ID=67515169
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502831A Active JP7319348B2 (ja) | 2018-07-19 | 2019-07-18 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117208A Active JP7586974B2 (ja) | 2018-07-19 | 2023-07-19 | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体およびそれらの使用 |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US11384153B2 (https=) |
| EP (2) | EP4516810A3 (https=) |
| JP (2) | JP7319348B2 (https=) |
| KR (1) | KR20210034032A (https=) |
| CN (1) | CN112423785B (https=) |
| AU (1) | AU2019307928B2 (https=) |
| BR (1) | BR112021000186A2 (https=) |
| CL (1) | CL2021000131A1 (https=) |
| CO (1) | CO2021000188A2 (https=) |
| CY (2) | CY1127721T1 (https=) |
| DK (1) | DK3823664T3 (https=) |
| ES (1) | ES3010285T3 (https=) |
| FI (2) | FI3823664T3 (https=) |
| FR (1) | FR25C1029I2 (https=) |
| HR (1) | HRP20250199T1 (https=) |
| HU (2) | HUE070224T2 (https=) |
| IL (1) | IL279974B2 (https=) |
| LT (2) | LT3823664T (https=) |
| MA (1) | MA53168B1 (https=) |
| MD (1) | MD3823664T2 (https=) |
| MX (2) | MX2021000488A (https=) |
| MY (1) | MY201816A (https=) |
| NL (1) | NL301335I2 (https=) |
| NO (1) | NO2025036I1 (https=) |
| PH (1) | PH12021550031A1 (https=) |
| PL (1) | PL3823664T3 (https=) |
| PT (1) | PT3823664T (https=) |
| RS (1) | RS66535B1 (https=) |
| SG (1) | SG11202100252SA (https=) |
| SI (1) | SI3823664T1 (https=) |
| SM (1) | SMT202500044T1 (https=) |
| TW (1) | TWI838389B (https=) |
| WO (1) | WO2020018820A1 (https=) |
| ZA (1) | ZA202100087B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110740641A (zh) | 2016-11-30 | 2020-01-31 | 杰克逊实验室 | 具有改善的人先天免疫细胞发育的人源化小鼠模型 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| IL270894B2 (en) | 2017-06-01 | 2023-04-01 | Regeneron Pharma | Human antibodies to bet v 1 and methods of using them |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| MD3823665T2 (ro) | 2018-07-19 | 2024-05-31 | Regeneron Pharma | Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora |
| CA3132587A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| LT3819007T (lt) | 2019-11-11 | 2024-10-10 | Amgen Research (Munich) Gmbh | Dozavimo režimas, skirtas anti-bcma agentams |
| CN114929343B (zh) * | 2019-12-06 | 2025-03-18 | 瑞泽恩制药公司 | 用双特异性抗BCMA x抗CD3抗体治疗多发性骨髓瘤的方法 |
| TW202144425A (zh) * | 2020-04-17 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 特異性抗原結合分子，其製備方法及醫藥用途 |
| JP7620780B2 (ja) * | 2020-06-30 | 2025-01-24 | ノナ・バイオサイエンシーズ・（シャンハイ）・カンパニー・リミテッド | Ｈ２Ｌ２とＨＣＡｂ構造を有する結合タンパク質 |
| AU2021300129A1 (en) | 2020-07-01 | 2022-12-08 | Regeneron Pharmaceuticals, Inc. | Methods of treating allergy using anti-Bet v 1 antibodies |
| WO2022053990A1 (en) * | 2020-09-14 | 2022-03-17 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| MX2023003214A (es) | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
| CN114524878B (zh) * | 2020-11-23 | 2024-08-02 | 康诺亚生物医药科技（成都）有限公司 | 一种双特异性抗体及其用途 |
| CN114573703A (zh) | 2020-12-02 | 2022-06-03 | 康诺亚生物医药科技（成都）有限公司 | 一种t细胞衔接器治疗剂的开发和应用 |
| PH12023500013A1 (en) | 2020-12-04 | 2024-03-11 | Tidal Therapeutics Inc | Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof |
| TW202246333A (zh) * | 2021-01-20 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｂｃｍａ和ｃｄ３的抗原結合分子及其醫藥用途 |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| CN115724996B (zh) * | 2021-08-30 | 2026-03-20 | 上海君赛生物股份有限公司 | 含有膜表面结构域的多肽及其用途 |
| WO2023098846A1 (zh) | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
| IL313760A (en) * | 2021-12-22 | 2024-08-01 | Jackson Lab | Human mouse models |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN117003871A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| US20230416396A1 (en) | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| IL317463A (en) | 2022-06-06 | 2025-02-01 | Shandong Simcere Biopharmaceutical Co Ltd | Multispecific antibodies targeting BCMA, GPRC5D and T cells and their application |
| WO2023240156A1 (en) | 2022-06-08 | 2023-12-14 | Tidal Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| CN115368466A (zh) * | 2022-07-19 | 2022-11-22 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| IL319818A (en) * | 2022-10-10 | 2025-05-01 | Regeneron Pharma | Methods for reducing alloantibody levels in patients requiring solid organ transplantation |
| CN117186230B (zh) * | 2022-12-06 | 2024-04-16 | 成都赛恩吉诺生物科技有限公司 | 包含亲水性氨基酸的抗人bcma纳米抗体的双特异性抗体及应用 |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| TW202502826A (zh) | 2023-06-06 | 2025-01-16 | 大陸商信達生物製藥（蘇州）有限公司 | 抗ｇｐｒｃ５ｄ／ｂｃｍａ／ｃｄ３三特異性抗體的製備及其用途 |
| TW202517293A (zh) | 2023-07-07 | 2025-05-01 | 美商再生元醫藥公司 | 含有抗bcmax抗cd3雙特異性抗體之穩定化配製物 |
| WO2025059362A1 (en) | 2023-09-13 | 2025-03-20 | Juno Therapeutics, Inc. | Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025131075A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3和抗cd3多特异性抗体及用途 |
| US20250242018A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025160324A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025174825A2 (en) | 2024-02-12 | 2025-08-21 | Aera Therapeutics, Inc. | Delivery compositions |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| TW202543585A (zh) | 2024-03-08 | 2025-11-16 | 美商健臻公司 | 脂質奈米粒子 |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025240287A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating light chain amyloidosis with bispecific bcma x cd3 antibodies |
| WO2025244973A1 (en) | 2024-05-20 | 2025-11-27 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific bcma x cd3 antibodies |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| WO2026059917A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with proteasome inhibitors |
| WO2026059919A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with cd38 inhibitors |
| WO2026059921A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
| WO2026059923A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with an immunomodulator |
| WO2026059920A1 (en) | 2024-09-10 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with pd1/pd-l1 inhibitors |
| WO2026072557A2 (en) | 2024-09-24 | 2026-04-02 | Genzyme Corporation | Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
| WO2026072709A1 (en) | 2024-09-25 | 2026-04-02 | Orna Therapeutics, Inc. | Chimeric antigen receptors targeting bcma |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CN100447244C (zh) | 1999-08-17 | 2008-12-31 | 比奥根艾迪克Ma公司 | Baff受体(bcma),一种免疫调节剂 |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| DE10206325A1 (de) | 2002-02-14 | 2003-09-04 | Medinnova Ges Med Innovationen | Ummantelter Mikroorganismus |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| PT3434767T (pt) | 2010-11-30 | 2026-01-23 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de citotoxicidade |
| UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
| KR101972446B1 (ko) | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RU2766608C2 (ru) | 2012-04-11 | 2022-03-15 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| US9243058B2 (en) | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Ｂｃｍａ抗原結合蛋白質 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| US20180112384A1 (en) | 2013-12-30 | 2018-04-26 | Craig Rothleitner | Drainage treatment system |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| ES2878449T3 (es) | 2014-07-24 | 2021-11-18 | 2Seventy Bio Inc | Receptores antigénicos quiméricos de BCMA |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
| SI3226897T1 (sl) | 2014-12-05 | 2021-08-31 | Memorial Sloan Kettering Cancer Center | Protitelesa, ki ciljajo na B-celični maturacijski antigen, in postopki uporabe |
| MY191537A (en) | 2014-12-05 | 2022-06-30 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| HRP20191873T1 (hr) | 2014-12-12 | 2020-01-24 | Bluebird Bio, Inc. | Kimerni antigenski receptori |
| TWI703159B (zh) | 2015-04-13 | 2020-09-01 | 美商輝瑞股份有限公司 | Bcma特異性治療性抗體及其用途 |
| US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
| CN115043943A (zh) | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| MX2018002043A (es) | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| CN108473575B (zh) | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | 抗-bcma多肽和蛋白质 |
| JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 組合せ処置およびその方法 |
| JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| CN108778329B (zh) | 2016-02-17 | 2022-09-16 | 西雅图基因公司 | Bcma抗体和其用以治疗癌症和免疫病症的用途 |
| TWI795133B (zh) | 2016-04-01 | 2023-03-01 | 美商凱特製藥公司 | Ｂｃｍａ結合分子類及彼等之用途 |
| SG10202012157QA (en) | 2016-06-07 | 2021-01-28 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Chimeric antigen receptor and car-t cells that bind bcma |
| EP3481410A2 (en) | 2016-07-08 | 2019-05-15 | Paul C. Tumeh | Compositions and treatment methods for cancer immunotherapy |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| WO2018075359A1 (en) | 2016-10-18 | 2018-04-26 | Boger Henry William | Wireless power transfer for process control |
| JP7267914B2 (ja) * | 2016-11-02 | 2023-05-02 | エンクマフ エスアーエールエル | Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬 |
| BR112019010878A2 (pt) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| WO2018133877A1 (zh) | 2017-01-23 | 2018-07-26 | 科济生物医药（上海）有限公司 | 靶向bcma的抗体及其应用 |
| EP3576793A4 (en) | 2017-02-06 | 2021-03-31 | Dana Farber Cancer Institute, Inc. | COMPOSITIONS AND PROCEDURES FOR ENHANCING ANTIBODY-MEDIATED RECEPTOR SIGNALING |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| US20200179511A1 (en) | 2017-04-28 | 2020-06-11 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| UY37726A (es) | 2017-05-05 | 2018-11-30 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| MA51447A (fr) | 2017-08-01 | 2020-06-10 | Medimmune Llc | Conjugué anticorps monoclonal-médicament dirigé contre bcma |
| CN111201243B (zh) | 2017-09-29 | 2023-08-11 | 财团法人牧岩生命科学研究所 | 对bcma具有高亲和力的抗bcma抗体和包含其的用于治疗癌症的药物组合物 |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| CN107827989A (zh) | 2017-10-18 | 2018-03-23 | 银丰生物工程集团有限公司 | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 |
| PT3674328T (pt) | 2018-02-01 | 2024-03-14 | Innovent Biologics Suzhou Co Ltd | Recetor de antigénio quimérico (car) que se liga a bcma e utilizações do mesmo |
| CA3101271A1 (en) * | 2018-05-24 | 2019-11-28 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| CA3132587A1 (en) * | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
-
2019
- 2019-07-17 TW TW108125183A patent/TWI838389B/zh active
- 2019-07-18 EP EP24212980.7A patent/EP4516810A3/en active Pending
- 2019-07-18 SG SG11202100252SA patent/SG11202100252SA/en unknown
- 2019-07-18 HR HRP20250199TT patent/HRP20250199T1/hr unknown
- 2019-07-18 MD MDE20210483T patent/MD3823664T2/ro unknown
- 2019-07-18 KR KR1020217004615A patent/KR20210034032A/ko active Pending
- 2019-07-18 JP JP2021502831A patent/JP7319348B2/ja active Active
- 2019-07-18 MA MA53168A patent/MA53168B1/fr unknown
- 2019-07-18 DK DK19749096.4T patent/DK3823664T3/da active
- 2019-07-18 LT LTEPPCT/US2019/042447T patent/LT3823664T/lt unknown
- 2019-07-18 CN CN201980047976.5A patent/CN112423785B/zh active Active
- 2019-07-18 SI SI201930882T patent/SI3823664T1/sl unknown
- 2019-07-18 IL IL279974A patent/IL279974B2/en unknown
- 2019-07-18 FI FIEP19749096.4T patent/FI3823664T3/fi active
- 2019-07-18 MX MX2021000488A patent/MX2021000488A/es unknown
- 2019-07-18 MY MYPI2021000039A patent/MY201816A/en unknown
- 2019-07-18 EP EP19749096.4A patent/EP3823664B1/en active Active
- 2019-07-18 HU HUE19749096A patent/HUE070224T2/hu unknown
- 2019-07-18 ES ES19749096T patent/ES3010285T3/es active Active
- 2019-07-18 BR BR112021000186-7A patent/BR112021000186A2/pt unknown
- 2019-07-18 PT PT197490964T patent/PT3823664T/pt unknown
- 2019-07-18 PL PL19749096.4T patent/PL3823664T3/pl unknown
- 2019-07-18 SM SM20250044T patent/SMT202500044T1/it unknown
- 2019-07-18 WO PCT/US2019/042447 patent/WO2020018820A1/en not_active Ceased
- 2019-07-18 AU AU2019307928A patent/AU2019307928B2/en active Active
- 2019-07-18 US US16/516,028 patent/US11384153B2/en active Active
- 2019-07-18 RS RS20250180A patent/RS66535B1/sr unknown
-
2021
- 2021-01-06 ZA ZA2021/00087A patent/ZA202100087B/en unknown
- 2021-01-06 PH PH12021550031A patent/PH12021550031A1/en unknown
- 2021-01-13 CO CONC2021/0000188A patent/CO2021000188A2/es unknown
- 2021-01-13 MX MX2025005515A patent/MX2025005515A/es unknown
- 2021-01-15 CL CL2021000131A patent/CL2021000131A1/es unknown
-
2022
- 2022-05-31 US US17/828,847 patent/US12258412B2/en active Active
-
2023
- 2023-07-19 JP JP2023117208A patent/JP7586974B2/ja active Active
-
2025
- 2025-02-19 US US19/057,229 patent/US20260008862A1/en active Pending
- 2025-04-04 CY CY20251100235T patent/CY1127721T1/el unknown
- 2025-07-08 LT LTPA2025526C patent/LTPA2025526I1/lt unknown
- 2025-07-14 NL NL301335C patent/NL301335I2/nl unknown
- 2025-07-16 CY CY2025020C patent/CY2025020I1/el unknown
- 2025-07-29 FR FR25C1029C patent/FR25C1029I2/fr active Active
- 2025-08-05 HU HUS2500032C patent/HUS2500032I1/hu unknown
- 2025-08-07 NO NO2025036C patent/NO2025036I1/no unknown
- 2025-08-14 FI FIC20253006C patent/FIC20253006I1/fi unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531005A5 (https=) | ||
| FI3823664T3 (fi) | Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä | |
| CN107405397B (zh) | 抗tim-3抗体 | |
| AU2016281641B2 (en) | Novel PD-1 immune modulating agents | |
| KR102340832B1 (ko) | 항 pd-1 항체 및 그의 용도 | |
| JP2023543152A5 (https=) | ||
| JP2022515611A5 (https=) | ||
| KR102838340B1 (ko) | 다중-특이적 항체 및 이들의 제조 및 사용 방법 | |
| JP2021527431A5 (https=) | ||
| JP2023505218A5 (https=) | ||
| JP2021506244A5 (https=) | ||
| EP3645741A2 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2020528750A5 (https=) | ||
| HRP20160009T1 (hr) | Protutijela anti-cd37 | |
| KR20170102167A (ko) | 항-pd-l1 항체 | |
| EP3341020A1 (en) | Pd-l1 ("programmed death-ligand 1") antibodies | |
| JP2022533538A5 (https=) | ||
| JP2020537520A (ja) | Ｃｄ１３７を標的とする抗体とその利用方法 | |
| RU2019104980A (ru) | Анти-icos антитела | |
| CN116041530A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2022514734A5 (https=) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| JP2024540148A5 (https=) | ||
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| CA3147887A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |